Brivaracetaminteractions

brivaracetam 25 MG Oral Tablet [Briviact]

This is the interactions section of this product’s FDA label — what the manufacturer documented for this drug. It is not a check of your medication list, and a drug missing from it has not been cleared: licensed clinical databases list far more interactions than any single label does. Before combining medicines, ask a pharmacist, who can check everything you take at once and will do it for free.

Named on this label

Every name above is printed in the text below. This is not the full set of drugs that interact with this one — it is the set this manufacturer wrote down.

Drug interactions

Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended.

Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT.

Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT.

Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam.

7.1 Rifampin

Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction. Prescribers should increase the BRIVIACT dose by up to 100% (i.e., double the dosage) in patients while receiving concomitant treatment with rifampin.

7.2 Carbamazepine

Co-administration with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine. Though available data did not reveal any safety concerns, if tolerability issues arise when co-administered, carbamazepine dose reduction should be considered.

7.3 Phenytoin

Because BRIVIACT can increase plasma concentrations of phenytoin, phenytoin levels should be monitored in patients when concomitant BRIVIACT is added to or discontinued from ongoing phenytoin therapy. 7.4 Levetiracetam BRIVIACT provided no added therapeutic benefit to levetiracetam when the two drugs were co-administered.

Text above is quoted in full from the FDA-approved drug label published by openFDA, effective August 20, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.

This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.

See what it costs — price without insurance